{"id":792790,"date":"2026-02-26T15:37:01","date_gmt":"2026-02-26T15:37:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=792790"},"modified":"2026-02-26T15:37:01","modified_gmt":"2026-02-26T15:37:01","slug":"lou-gehrigs-disease-clinical-trial-pipeline-shows-potential-with-active-contributions-from-75-key-companies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lou-gehrigs-disease-clinical-trial-pipeline-shows-potential-with-active-contributions-from-75-key-companies-delveinsight_792790.html","title":{"rendered":"Lou Gehrig\u2019s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1772103574.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lou Gehrig&rsquo;s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1772103574.jpg\" alt=\"Lou Gehrig&rsquo;s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<strong>Lou Gehrig&rsquo;s disease Pipeline Insight, 2026<\/strong>&rdquo; report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Lou Gehrig&rsquo;s disease pipeline landscape. It covers the Lou Gehrig&rsquo;s disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lou Gehrig&rsquo;s disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the Lou Gehrig&rsquo;s Disease Pipeline. Dive into DelveInsight&#8217;s comprehensive report today! @<\/strong> <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Lou Gehrig&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><em>On February 02, 2026- PhenoNet Inc<\/em><\/strong>. announced a study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.<\/li>\n<li><strong><em>In January 2026, Merit E. Cudkowicz, MD<\/em><\/strong> conducted a HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is registered as NCT04297683. Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the participant will be eligible to be randomized into any currently enrolling regimen. All participants will have an equal chance of being randomized to any currently enrolling regimen.<\/li>\n<li>DelveInsight&rsquo;s Lou Gehrig&rsquo;s Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Lou Gehrig&rsquo;s Disease treatment.<\/li>\n<li>The leading Lou Gehrig&rsquo;s Disease Companies such as <strong><em>Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB<\/em><\/strong> and others.<\/li>\n<li>Promising Lou Gehrig&rsquo;s Disease Pipeline Therapies such as <strong><em>Ulefnersen, MN-166, RNS60, QRL-201 <\/em><\/strong>and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Lou Gehrig&rsquo;s Disease Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lou Gehrig&rsquo;s Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Ulefnersen: Ionis Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ulefnersen, formerly known as ION363, is an investigational antisense medicine designed to reduce the production of the fused in sarcoma (FUS) protein to treat people with amyotrophic lateral sclerosis (ALS) caused by mutations in the FUS gene. Ulefnersen is also known as Jacifusen (not an official USAN name) in honor of Jaci Hermstad, the first patient treated with the drug under an expanded access program. Because antisense-mediated reduction of mutant FUS protein in a FUS-ALS mouse model demonstrated the ability to prevent motor neuron loss, it is hypothesized that reduction of FUS protein will reverse or prevent disease progression in FUS-ALS patients. The drug is currently being evaluated under Phase III clinical trial for the treatment of ALS.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>MN-166: MediciNova<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1&szlig;, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II\/III clinical trial for the treatment of ALS.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>RNS60: Revalesio<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>QRL-201: QurAlis Corporation<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the treatment of ALS.<\/p>\n<p style=\"text-align: justify;\"><strong>The Lou Gehrig&rsquo;s Disease Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Lou Gehrig&rsquo;s Disease with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lou Gehrig&rsquo;s Disease Treatment.<\/li>\n<li>Lou Gehrig&rsquo;s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Lou Gehrig&rsquo;s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lou Gehrig&rsquo;s Disease market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the Lou Gehrig&rsquo;s Disease Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">New Lou Gehrig&rsquo;s Disease Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Lou Gehrig&rsquo;s Disease Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Lou Gehrig&rsquo;s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Lou Gehrig&rsquo;s Disease Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn about new drugs, pipeline developments, and key companies with DelveInsight&#8217;s expert analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Lou Gehrig&rsquo;s Disease Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Lou Gehrig&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Lou Gehrig&rsquo;s Disease Companies- <strong><em>Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB<\/em><\/strong> and others.<\/li>\n<li>Lou Gehrig&rsquo;s Disease Pipeline Therapies- <strong><em>Ulefnersen, MN-166, RNS60, QRL-201 <\/em><\/strong>and others.<\/li>\n<li>Lou Gehrig&rsquo;s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Lou Gehrig&rsquo;s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Download DelveInsight&#8217;s in-depth Lou Gehrig&rsquo;s Disease Pipeline report today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lou-gehrigs-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">Lou Gehrig&rsquo;s Disease Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Lou Gehrig&rsquo;s disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Lou Gehrig&rsquo;s disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Ulefnersen: Ionis Pharmaceuticals<\/li>\n<li>Mid Stage Products (Phase II\/III)<\/li>\n<li>MN-166: MediciNova<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>QRL-201: QurAlis Corporation<\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug name: Company name<\/li>\n<li>Inactive Products<\/li>\n<li>Lou Gehrig&rsquo;s disease Key Companies<\/li>\n<li>Lou Gehrig&rsquo;s disease Key Products<\/li>\n<li>Lou Gehrig&rsquo;s disease- Unmet Needs<\/li>\n<li>Lou Gehrig&rsquo;s disease- Market Drivers and Barriers<\/li>\n<li>Lou Gehrig&rsquo;s disease- Future Perspectives and Conclusion<\/li>\n<li>Lou Gehrig&rsquo;s disease Analyst Views<\/li>\n<li>Lou Gehrig&rsquo;s disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lou-gehrigs-disease-clinical-trial-pipeline-shows-potential-with-active-contributions-from-75-key-companies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/lou-gehrigs-disease-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/lou-gehrigs-disease-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lou-gehrigs-disease-clinical-trial-pipeline-shows-potential-with-active-contributions-from-75-key-companies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s &ldquo;Lou Gehrig&rsquo;s disease Pipeline Insight, 2026&rdquo; report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Lou Gehrig&rsquo;s disease pipeline landscape. It covers the Lou Gehrig&rsquo;s disease pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lou-gehrigs-disease-clinical-trial-pipeline-shows-potential-with-active-contributions-from-75-key-companies-delveinsight_792790.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-792790","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/792790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=792790"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/792790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=792790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=792790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=792790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}